Health ❯ Pharmaceuticals

Drug Research

Clinical Trials Protein Functions Therapeutic Drug Candidate Drug Pipeline Inflammatory Disorders Immunology Bioactive Compounds RNA-Based Treatments Molecular Therapies AI-Driven Drug Discovery

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Emory Revamps Chan–Evans–Lam Reaction to Expand Access to Vinylic Ethers

Peer-Reviewed OU Study Maps Amylin Receptors, Offering Tools for Next‑Gen Obesity Drugs